Abstract
Purpose
We recently developed a cysteine-containing peptide tag (C-tag) that allows for site-specific modification of C-tag-containing fusion proteins with a bifunctional chelator, HYNIC (hydrazine nicotinamide)-maleimide. We then constructed and expressed C-tagged vascular endothelial growth factor (VEGF) and labeled it with HYNIC. We wished to test 99mTc-HYNIC-C-tagged VEGF (99mTc-HYNIC-VEGF) for the imaging of tumor vasculature before and after antiangiogenic (low continuous dosing, metronomic) and tumoricidal (high-dose) cyclophosphamide treatment.
Methods
HYNIC-maleimide was reacted with the two thiol groups of C-tagged VEGF without any effect on biologic activity in vitro. 99mTc-HYNIC-VEGF was prepared using tin/tricine as an exchange reagent, and injected via the tail vein (200–300 μCi, 1–2 μg protein) followed by microSPECT imaging 1 h later.
Results
Sequencing analysis of HYNIC-containing peptides obtained after digestion confirmed the site-specific labeling of the two accessible thiol groups of C-tagged VEGF. Tumor vascularity was easily visualized with 99mTc/VEGF in Balb/c mice with 4T1 murine mammary carcinoma 10 days after implantation into the left axillary fat pad in controls (12.3±5.0 tumor/bkg, n=27) along with its decrease following treatment with high (150 mg/kg q.o.d. ×4; 1.14±0.48 tumor/bkg, n=9) or low (25 mg/kg q.d. ×7; 1.03±0.18 tumor/bkg, n=9) dose cyclophosphamide. Binding specificity was confirmed by observing a 75% decrease in tumor uptake of 99mTc/biotin-inactivated VEGF, as compared with 99mTc-HYNIC-VEGF.
Conclusion
99mTc can be loaded onto C-tagged VEGF in a site-specific fashion without reducing its bioactivity. 99mTc-HYNIC-VEGF can be rapidly prepared for the imaging of tumor vasculature and its response to different types of chemotherapy.
Similar content being viewed by others
References
Ferrara N. Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev 2004;25:581–611
Underiner TL, Ruggeri B, Gingrich DE. Development of vascular endothelial growth factor receptor (VEGFR) kinase inhibitors as anti-angiogenic agents in cancer therapy. Curr Med Chem 2004;11:731–745
Hristov M, Erl W, Weber PC. Endothelial progenitor cells: mobilization, differentiation, and homing. Arterioscler Thromb Vasc Biol 2003;23:1185–1189
Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002;20:4368–4380
Blankenberg FG, Mandl S, Cao YA, O’Connell-Rodwell C, Contag C, Mari C, et al. Tumor imaging using a standardized radiolabeled adapter protein docked to vascular endothelial growth factor. J Nucl Med 2004;45:1373–1380
Backer MV, Gaynutdinov TI, Gorshkova II, Crouch RJ, Hu T, Aloise R, et al. Humanized docking system for assembly of targeting drug delivery complexes. J Control Release 2003;89:499–511
Backer MV, Gaynutdinov TI, Patel V, Bandyopadhyaya AK, Thirumamagal BTS, Tjarks W, et al. Vascular endothelial growth factor selectively targets boronated dendrimers to tumor vasculature. Mol Cancer Ther 2005;4:1423–1429
Backer MV, Elliot J, Gaynutdinov TI, Backer JM. Assembly of targeting complexes driven by a single-chain antibody. J Immunol Meth 2004;289:35–43
Backer MV, Aloise R, Przekop K, Stoletov K, Backer JM. Molecular vehicles for targeted drug delivery. Bioconjug Chem 2002;13:462–467
Backer MV, Backer JM. Functionally active VEGF fusion proteins. Prot Express Purif 2001;23:1–7
Backer MV, Backer JM. Targeting endothelial cells overexpressing VEGFR-2: selective toxicity of Shiga-like toxin-VEGF fusion proteins. Bioconj Chem 2001;12:1066–1073
Larsen SK, Solomon HF, Caldwell G, Abrams MJ. [99mTc]tricine: a useful precursor complex for the radiolabeling of hydrazinonicotinate protein conjugates Bioconjugate Chemistry 1995;6:635–638
LaCroix KJ, Tsui BM, Frey EC, Jaszczak RJ. Receiver operating characteristic evaluation of iterative reconstruction with attenuation correction in 99mTc-sestamibi myocardial SPECT images. J Nucl Med 2000;41:502–513
Lalush DS, Frey EC, Tsui BM. Fast maximum entropy approximation in SPECT using the RBI-MAP algorithm. IEEE Trans Med Imaging 2000;19:286–294
Lalush DS, Tsui BM. Performance of ordered-subset reconstruction algorithms under conditions of extreme attenuation and truncation in myocardial SPECT. J Nucl Med 2000;41:737–744
Blankenberg F, Backer M, Patel V, Jehning B, Levashova Z, Backer J. Imaging of tumor angiogenesis with 99mTc-labeled single chain (sc)VEGF. 2005: Late-Breaking Abstract Number: 585; 4th Annual Meeting of the Society of Molecular Imaging
Man S, Bocci G, Francia G, Green SK, Jothy S, Hanahan D, et al. Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. Cancer Res 2002;62:2731–2735
Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, et al. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res 2004;64:3994–4000
Acknowledgements
The work was supported by 1R43 CA113080 and 1 R21 EB001946 to J. Backer.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Blankenberg, F.G., Backer, M.V., Levashova, Z. et al. In vivo tumor angiogenesis imaging with site-specific labeled 99mTc-HYNIC-VEGF. Eur J Nucl Med Mol Imaging 33, 841–848 (2006). https://doi.org/10.1007/s00259-006-0099-1
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00259-006-0099-1